Gilead Sciences, Inc. (GILD), Apple Inc. (AAPL), Johnson & Johnson (JNJ): Favorite Picks Of Stillwater Investment Management

Stillwater Investment Management has a 13F portfolio value of $141.99 million, as per its recent SEC 13F filing on October 6, 2014. Its top 10 holdings amount for 47.91% of its overall portfolio. Apple Inc. (NASDAQ:AAPL), Gilead Sciences, Inc. (NASDAQ:GILD), Johnson & Johnson (NYSE:JNJ) are among the top stock holdings of Stillwater Investment Management.

With a proven performance of several years and the iconic iPhone in its portfolio, Apple Inc. (NASDAQ:AAPL) makes it to the portfolio of several hedge funds including Stillwater Investment Management, which owns 47,821 shares of the company with market value of $4.81 million. The iPhone maker generated net revenue of $37.4 billion in its third quarter 2014 while generating net profits of $7.7 billion. Some of the primary investors of Apple Inc (NASDAQ:AAPL) include Icahn Capital investing $4.9 billion in the company. Soroban Capital Partners is the second largest investor at $2.46 billion followed by Citadel Investment Group ($1.61 billion).

Gilead Sciences, Inc. (NASDAQ:GILD) comes at number two in Stillwater Investment Management’s portfolio with 33,403 shares and investments exceeding $3.55 million. Gilead Sciences, Inc. (NASDAQ:GILD) managed to generate net revenues of $6.53 billion during the second quarter 2014 with its net income standing at $3.66 billion. When it comes to the investors of Gilead Sciences, Inc. (NASDAQ:GILD), Egerton Capital Limited is comes first at $509 million with Orbis Investment Management standing at number two ($509 million) and Columbus Circle Investors ($398 million) comes at number three.

Gilead Sciences, Inc. (GILD)

Stillwater Investment Management has Johnson & Johnson (NYSE:JNJ) as its third largest investment with investments standing at $3.22 million and 30,228 shares. Johnson & Johnson (NYSE:JNJ) raised net sales of $19.5 billion in the second quarter 2014 and registered net earnings of $4.3 billion. Some of its primary investors include Fisher Asset Management ($1.09 billion), Yacktman Asset Management ($946 million), and Aqr Capital Management ($381 million).

This article has been written by Prakash Pandey and edited by Serkan Unal.

Related News: “Gilead Sciences, Inc. (GILD) Says Pancreatic Cancer Treatment, Simtuzumab, Failed to Meet Trial Goals in Phase II”

“Gilead Sciences, Inc. (GILD) Strikes Deal for Cheaper Hepatitis C Drugs for Developing Countries”

Read: Warren Buffett and Billionaires Are Crazy About These 7 Stocks

Read: The 10 Most Used Social Media Websites Today



Related posts


Warren Buffett's Best Picks

Warren Buffett's these stock picks will crush the market over the next 12 months. Get our report FREE by becoming a member now